Ascentage Pharma (6855 HK)

Analysis

Health Care • China

Ascentage Pharma is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel small-molecule therapies for cancers, hepatitis B virus, and certain age-related diseases. The company specializes in therapies that inhibit protein-protein interactions to restore programmed cell death, with lead assets including olverembatinib and lisaftoclax for hematological malignancies. Ascentage Pharma was founded in 2009 and is headquartered in Suzhou, China.

Refresh

Company Presentation • 20 Aug 2026 18:20

H1 2026

Company Presentation • 14 Jan 2021 17:00

Investor presentation

Company Presentation • 10 Jan 2022 17:00

Investor presentation

Company Presentation • 13 Jan 2023 17:00

Investor presentation

Company Presentation • 10 Jan 2024 17:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00